Effect of long-term proton pump inhibitor therapy and healing effect of irsogladine on nonsteroidal anti-inflammatory drug-induced small-intestinal lesions in healthy volunteers

Journal of Clinical Biochemistry and Nutrition

Volumn 57, Issue 1, 2015, Pages 60-65

  Kojima, Yuichi ^a   Takeuchi, Toshihisa ^a   Ota, Kazuhiro ^a   Harada, Satoshi ^a   Edogawa, Shoko ^a   Narabayashi, Ken ^a   Nouda, Sadaharu ^a   Okada, Toshihiko ^a   Kakimoto, Kazuki ^a   Kuramoto, Takanori ^a   Inoue, Takuya ^a   Higuchi, Kazuhide ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Capsule endoscopy; Irsogladine; NSAIDs; PPI; Small bowel

Indexed keywords

DICLOFENAC; IRSOGLADINE; OMEPRAZOLE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CAPSULE ENDOSCOPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; INTESTINE INJURY; LONG TERM CARE; MALE; RANDOMIZED CONTROLLED TRIAL;

EID: 84938379258     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.15-32     Document Type: Article

References (30)

1. Higuchi K, Umegaki E, Watanabe T, et al. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 2009; 44: 879-888
2. Handa O, Naito Y, Fukui A, Omatsu T, Yoshikawa T. The impact of non-steroidal anti-inflammatory drugs on the small intestinal epithelium. J Clin Biochem Nutr 2014; 54: 2-6
3. Watanabe T, Higuchi K, Kobata A, et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 2008; 57: 181-187
4. Yoda Y, Takeuchi K, Kato S, et al. Search for prophylactic drugs against NSAID-induced small intestinal lesions in rats. Gastroenterology 2008; 134(Suppl 1): A528
5. Akagi M, Amagase K, Murakami T, Takeuchi K. Irsogladine: overview of the mechanisms of mucosal protective and healing-promoting actions in the gastrointestinal tract. Curr Pharm Des 2013; 19: 106-114
6. Kamei K, Kubo Y, Kato N, Hatazawa R, Amagase K, Takeuchi K. Prophylactic effecgt of irsogladine maleate against indomethacin-induced small intestinal lesions in rats. DigDis Sci 2008; 53: 2657-2666
7. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastro- enterology 2011; 141: 1314-1322
8. Satoh H, Amagase K, Takeuchi K. Exacerbation of nonsteroidal anti-inflammatory drug-induced small intestinal lesions by antisecretory durgs in rats: the role of intestinal motility. J Pharmacol Exp Therap 2012; 343: 270277
9. Kuramoto K, Umegaki E, Nouda S, et al. Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. BMC Gastroenterol 2013; 13: 85
10. Niwa Y, Nakamura M, Ohmiya N, et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injury in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled cross-over study. JGstroenterol 2008; 43: 270-276
11. Fujimori S, Takahashi Y, Gudis K, et al. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol 2011; 46: 57-64
12. Fujimori S, Seo T, Gudis K, et al. Prevention of nonsteroidal anti-inflammatory drug-induced small intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc 2009; 69: 1339-1346
13. Goldstein JL, Eisen GM, Lewis B, Grainek IM, Ziotnick S, Fort JG; Investigators. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastro- enterol Hepatol 2005; 3: 133-141
14. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55-59
15. Tytgat GN. Etiopathogenetic principles and peptic ulcer disease classification. Dig Dis 2011; 29: 454-458
16. Satoh H. Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity. Curr Pharm Des 2013; 19: 67-75
17. Kuwayama H, Eastwood G, Miyake S, Furukawa H. Adaptation of gastric mucosa to repeated indomethacin administration in the rat. Gastroenterology 1986; 90: 1506
18. Kawai T, Yamagishi T, Goto S. Circadian variations of gastrointestinal mucosal damage detected with transnasal endoscopy in apparently healthy subjects treated with low-dose aspirin for a short period. J Atheroscler Thromb 2009; 16: 155-163
19. Alderman BM, Ulaganathan M, Judd LM, et al. Insights into the mechanisms of gastric adaptation to aspirin-induced injury: a role for regenerating protein but not trefoil peptides. Lab Invest 2003; 83: 1415-1425
20. Konturek JW, Dembinski A, Konturek SJ, Domschke W. Helicobacter pylori and gastric adaptation to repeated aspirin administration in humans. J Physiol Pharmacol 1997; 48: 383-391
21. Lipscomb GR, Wallis N, Armstrong G, Goodman MJ, Rees WD. Influence of Helicobacter pylori on gastric mucosal adaptation to naproxen in man. Dig Dis Sci 1996; 41: 1583-1588
22. Shorrock CJ, Rees WD. Mucosal adaptation to indomethacin induced gastric damage in man-studies on morphology, blood flow and prostaglandin E2 metabolism. Gut 1992; 33: 164-169
23. Mizukami K, Murakami K, Abe T, et al. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol 2011; 17: 5117-5122
24. Endo H, Hosono K, Inamori M, et al. Incidence of small bowel injury induced by low-dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion 2009; 79: 44-51
25. Niwa Y, Nakamura M, Miyahara R, et al. Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects: a prospective randomized placebo-controlled double-blind cross-over study. Digestion 2009; 80: 260-266
26. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172-1178
27. Goldstein JL, Eisen GM, Lewis B, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 2007; 25: 1211-1222
28. Shiotani A, Haruma K, Nishi R, et al. Randomized double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin induced small bowel damage. Scand J Gastroenterol 2010; 45: 292-298
29. Smecuol E, Pinto Sanchez MI, Suarez A, et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol 2009; 7: 524-529
30. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992; 327: 749-754